Alembic Pharma Secures USFDA Final Approval for Dapagliflozin Tablets

Alembic Pharmaceuticals has earned final approval from the U.S. Food and Drug Administration (USFDA) for its Dapagliflozin Tablets, available in 5 mg and 10 mg strengths. This milestone allows Alembic to pursue 180 days of shared generic drug exclusivity in the U.S. market. The drug is approved for treating heart failure and improving blood sugar control in adults with type 2 diabetes.

The U.S. market for Dapagliflozin Tablets was valued at over $10.4 billion in the 12 months ending December 2025.

USFDA Approval Granted

Alembic Pharmaceuticals announced it has received final clearance from the USFDA for its Dapagliflozin Tablets, in both 5 mg and 10 mg strengths.

This clearance is significant, positioning Alembic for a 180-day period of shared generic drug exclusivity in the competitive U.S. market. The drug treats adults with type 2 diabetes to improve glycemic control and also helps adults with heart failure.

Market Opportunity

The USFDA approval unlocks access for Alembic to a substantial U.S. market. The upcoming exclusivity period offers a critical competitive advantage upon launch, with the potential to significantly boost the company's revenue.

Development History

This final approval follows a history of engagement with the USFDA. Alembic Pharmaceuticals previously received a tentative approval for these tablets on July 23, 2019. The company has been steadily expanding its U.S. generics portfolio, aiming for consistent product launches. To date, Alembic Pharmaceuticals holds 235 USFDA ANDA approvals, including 217 final and 18 tentative.

Key Impacts

• Market Entry: Alembic can now develop and execute its launch strategy for Dapagliflozin Tablets in the U.S.
• Revenue Boost: The 180-day exclusivity period is anticipated to drive initial sales and contribute to revenue growth.
• Portfolio Expansion: This approval adds another key generic product to Alembic's growing U.S. offerings.
• Therapeutic Positioning: The clearance strengthens Alembic's standing in the U.S. cardiovascular and diabetes therapeutic segments.

Competitive Landscape

Despite the positive approval, Alembic faces significant competition within the U.S. generics market. The actual market penetration and subsequent revenue will depend on the effectiveness of its commercial strategies and pricing.

Peer Activity

Other Indian pharmaceutical companies are also active in the U.S. generics arena. Lupin Limited and Zydus Lifesciences have received tentative approvals for Dapagliflozin Tablets, indicating a crowded competitive field. Sun Pharmaceutical Industries maintains a strong presence in these therapeutic areas in the U.S.

Market Data

• The estimated market size for Dapagliflozin Tablets was US$ 10,487 million for the twelve months ending December 2025.
• Alembic is eligible for a 180-day period of shared generic drug exclusivity in the U.S. market upon launch.

What to Watch

Key developments to monitor include Alembic's official launch date in the U.S. market. Investors will also track market share gains, revenue performance during the exclusivity period, and the company's ongoing ANDA pipeline. Observing how competing generic players launch and market their versions of Dapagliflozin will provide further context.